

Preprint for bioRxiv

Improved vectors and genome-wide libraries for CRISPR screening

Neville E. Sanjana^{1,2,3,4,5}, Ophir Shalem^{1,2,3,4,5} and Feng Zhang^{1,2,3,4}

¹ Broad Institute of MIT and Harvard
7 Cambridge Center
Cambridge, MA 02142, USA

² McGovern Institute for Brain Research
Massachusetts Institute of Technology
Cambridge, MA 02139, USA

³ Department of Brain and Cognitive Sciences
Massachusetts Institute of Technology
Cambridge, MA 02139, USA

⁴ Department of Biological Engineering
Massachusetts Institute of Technology
Cambridge, MA 02139, USA

⁵ These authors contributed equally to this work.
email: zhang@broadinstitute.org

Genome-wide, targeted loss-of-function pooled screens using the CRISPR (clustered regularly interspaced short palindrome repeats)-associated nuclease Cas9 in human and mouse cells provide an alternative screening system to RNA interference (RNAi) and have been used to reveal new mechanisms in diverse biological models¹⁻⁴. Previously, we used a Genome-scale CRISPR Knock-Out (GeCKO) library to identify loss-of-function mutations conferring vemurafenib resistance in a melanoma model¹. However, initial lentiviral delivery systems for CRISPR screening had low viral titer or required a cell line already expressing Cas9, limiting the range of biological systems amenable to screening.

Here, we sought to improve both the lentiviral packaging and choice of guide sequences in our original GeCKO library¹, where a pooled library of synthesized oligonucleotides was cloned into a lentiviral backbone containing both the *Streptococcus pyogenes* Cas9 nuclease and the single guide RNA (sgRNA) scaffold. To create a new vector capable of producing higher-titer virus (lentiCRISPRv2), we made several modifications, including removal of one of the nuclear localization signals (NLS), human codon-optimization of the remaining NLS and P2A bicistronic linker sequences, and repositioning of the U6-driven sgRNA cassette (**Fig. 1a**). These changes resulted in a ~10-fold increase in functional viral titer over lentiCRISPRv1¹ (**Fig. 1b**).

To further increase viral titer, we also cloned a two-vector system, in which Cas9 (lentiCas9-Blast) and sgRNA (lentiGuide-Puro) are delivered using separate viral vectors with distinct antibiotic selection markers (**Fig. 1a**). LentiGuide-Puro has a ~100-fold increase in functional viral titer over the original lentiCRISPRv1 (**Fig. 1b**). Both single and dual-vector systems mediate efficient knock-out of a genetically-integrated copy of EGFP in human cells (**Supplementary Fig. 1**). Whereas the dual vector system enables generation of Cas9-expressing cell lines which can be subsequently used for screens using lentiGuide-Puro, the single vector lentiCRISPRv2 may be better suited for *in vivo* or primary cell screening applications.

In addition to the vector improvements, we designed and synthesized new human and mouse GeCKOv2 sgRNA libraries (**Supplementary Methods**) with several improvements (**Table 1**): First, for both human and mouse libraries, to target all genes with a uniform number of sgRNAs, we selected 6 sgRNAs per gene distributed over 3-4 constitutively expressed exons. Second, to further minimize off-target genome modification, we improved the calculation of off-target scores based on specificity analysis⁵. Third, to inactivate microRNAs (miRNAs) which play a key role in transcriptional regulation, we added sgRNAs to direct mutations to the pre-miRNA hairpin structure⁶. Finally, we targeted ~1000 additional genes not included in the original GeCKO library.

Both libraries, mouse and human, are divided into 2 sub-libraries — containing 3 sgRNAs targeting each gene in the genome, as well as 1000 non-targeting control sgRNAs. Screens can be performed by combining both sub-libraries, yielding 6 sgRNAs per gene, for higher coverage. Alternatively, individual sub-libraries can be used in situations where cell numbers are limiting (eg. primary cells, *in vivo* screens). The human and mouse libraries have been cloned into lentiCRISPRv2 and into lentiGuide-Puro and deep sequenced to ensure uniform representation (**Supplementary Fig. 2, 3**). These new lentiCRISPR vectors and human and mouse libraries further improve the GeCKO reagents for diverse screening applications. Reagents are available to the academic community through Addgene and associated protocols, support forums, and computational tools are available via the Zhang lab website (www.genome-engineering.org).

Acknowledgements: We also would like to thank the entire Zhang Lab for support and helpful advice. N.S. is supported by a postdoctoral fellowship from the Simons Center for the Social Brain at MIT. O.S. is a Klarman Fellow of the Broad-Israel Partnership. F.Z. is supported by the NIH and NIMH through a Director's Pioneer Award (5DP1-MH100706), a Transformative R01 grant (5R01-DK097768), the Keck, Merkin, Vallee,

Damon Runyon, Searle Scholars, Klingenstein, and Simons Foundations, Bob Metcalfe, and Jane Pauley.

Author Contributions

N.S., O.S., and F.Z. conceived and designed the experiments. N.S. and O.S. performed the experiments and analyzed the data. N.S., O.S., and F.Z. wrote the manuscript.


Competing Financial Interests

A patent application has been filed relating to this work, and the authors plan on making the reagents widely available to the academic community through Addgene and to provide software tools via the Zhang lab website (<http://www.genome-engineering.org/>). F.Z. is a scientific advisor for Editas Medicine.

References

1. Shalem, O. *et al. Science* **343**, 84–87 (2014).
2. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. *Science* **343**, 80–84 (2014).
3. Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C. & Yusa, K. *Nat Biotechnol* **32**, 267–273 (2013).
4. Zhou, Y. *et al. Nature* **509**, 487–491 (2014).
5. Hsu, P. D. *et al. Nat Biotechnol* **31**, 827–832 (2013).
6. Zhao, Y. *et al. Sci Rep* **4**, 3943 (2014).

Figure 1 | New lentiviral CRISPR designs produce viruses with higher functional titer.



(a) Lentiviral expression vector for *Streptococcus pyogenes* Cas9 and sgRNA in the improved one vector system (lentiCRISPR v2) and the two vector system (lentiCas9-Blast, lentiGuide-Puro). Psi packaging signal (psi+), rev response element (RRE), central polypurine tract (cPPT), elongation factor-1 α short promoter (EFS), FLAG octapeptide tag (FLAG), 2A self-cleaving peptide (P2A), puromycin selection marker (puro), posttranscriptional regulatory element (WPRE), blasticidin selection marker (blast), and elongation factor-1 α promoter (EF1a). **(b)** Relative functional viral titer of viruses made from lentiCRISPR v1¹, lentiCRISPR v2, and lentiGuide-Puro vector with a EGFP-targeting sgRNA ($n = 3$ independently-transfected virus batches with 3 replicate transductions per construct). HEK293FT cells were transduced with serial dilutions of virus and, after 24 hours, selected using puromycin (1 ug/ml). Puromycin-resistant cells were measured after 4 days from the start of selection using the CellTiter-Glo (Promega) luciferase assay. Relative titers were calculated using viral volumes that yielded less than 20% puromycin-resistant cells in order to minimize the number of cells with multiple infections. Numbers above each bar indicate the size of the packaged virus for each construct.

Table 1 | Comparison of new GeCKO v2 human and mouse sgRNA libraries with existing CRISPR libraries.

	Wang et al. (2014) library	Shalem et al. (2014) GeCKO v1 library	Yusa et al. (2014) library	GeCKO v2 human library	GeCKO v2 mouse library
<i>Species</i>	human	human	mouse	human	mouse
<i>Number of genes targeted</i>	7,114	18,080	19,150	19,050	20,611
<i>Targeting constructs per gene</i>	10 per gene	variable (typically 3 to 4 per gene)	variable (typically 4 to 5 per gene)	6 per gene (3 in Library A, 3 in Library B)	6 per gene (3 in Library A, 3 in Library B)
<i>Number of miRNA targeted</i>	none	none	none	1,864	1,175
<i>Targeting constructs per miRNA</i>	n/a	n/a	n/a	4 per miRNA	4 per miRNA
<i>Control (non-targeting) sgRNAs</i>	100	none	none	1,000	1,000
<i>Total sgRNA constructs</i>	73,151	64,751	87,897	123,411 (65,383 in Library A, 58,028 in Library B)	130,209 (67,405 in Library A, 62,804 in Library B)
<i>Viral plasmid vector</i>	Dual vector: sgRNA only	Single vector: Cas9 and sgRNA (lentiCRISPR v1)	Dual vector: sgRNA only	Single and dual vector: lentiCRISPR v2 and lentiGuide-Puro	Single and dual vector: lentiCRISPR v2 and lentiGuide-Puro

New GeCKO libraries target an increased number of genes with uniform coverage (6 sgRNAs per gene divided into sub-libraries with 3 sgRNAs per gene). The GeCKO v2 libraries also contain sgRNAs that target microRNAs and control sgRNAs that do not target in the genome. The libraries have been cloned into lentiCRISPR v2 (which includes Cas9 in the same vector) and lentiGuide-Puro (sgRNA-only vector) and are available in either format.

Supplementary Materials

Improved vectors and genome-wide libraries for CRISPR screening

Neville E. Sanjana^{1,2,3,4,5}, Ophir Shalem^{1,2,3,4,5} and Feng Zhang^{1,2,3,4}

¹ Broad Institute of MIT and Harvard

7 Cambridge Center

Cambridge, MA 02142, USA

² McGovern Institute for Brain Research

³ Department of Brain and Cognitive Sciences


⁴ Department of Biological Engineering

Massachusetts Institute of Technology

Cambridge, MA 02139, USA


⁵ These authors contributed equally to this work.
email: zhang@broadinstitute.org.

Supplementary Figure 1 | EGFP expression in HEK293T-EGFP cells after transduction with different lentiviral CRISPR constructs.




(a) Representative histograms of EGFP fluorescence from single transductions of HEK293T-EGFP cells with lentiCRISPR v1, lentiCRISPR v2, lentiGuide-Puro or no virus. For lentiGuide-Puro, HEK293T-EGFP cells had previously been transduced with lentiCas9-Blast and selected for 4 days with blasticidin. Twenty-four hours after transduction, cells were selected in puromycin and then analyzed by flow cytometry at 7 days after infection. **(b)** Percentage of EGFP positive cells (as given by gate drawn in **a**) per viral construct (error bars indicate s.e.m, $n=3$ biological replicate transductions).

Supplementary Figure 2 | Sequencing of human GeCKOv2 libraries cloned into lentiCRISPRv2 and lentiGuide-Puro.



Histograms of sgRNA representation after cloning each half-library into sgRNA vectors. Inset: Cumulative distribution of sequencing reads. The number of sequencing reads for the 10th and 90th sgRNA percentile is indicated by the dashed red lines and text labels. All library sequencing was performed with PCR replicates; only one replicate is shown for each half-library. **(a,b)** Human GeCKOv2 library A (**a**) and library B (**b**) in lentiCRISPRv2. **(c,d)** Human GeCKOv2 library A (**c**) and B (**d**) in lentiGuide-Puro.

Supplementary Figure 3 | Sequencing of mouse GeCKOv2 libraries cloned into lentiCRISPRv2 and lentiGuide-Puro.



Histograms of sgRNA representation after cloning each half-library into sgRNA vectors. Inset: Cumulative distribution of sequencing reads. The number of sequencing reads for the 10th and 90th sgRNA percentile is indicated by the dashed red lines and text labels. All library sequencing was performed with PCR replicates; only one replicate is shown for each half-library. **(a,b)** Mouse GeCKOv2 library A **(a)** and library B **(b)** in lentiCRISPRv2. **(c,d)** Mouse GeCKOv2 library A **(c)** and B **(d)** in lentiGuide-Puro.

Supplementary Methods

Lentiviral cloning and production. For determination of lentiCRISPR v1, lentiCRISPR v2, and lentiGuide-Puro viral titers, the following sgRNA targeting EGFP (with no known targets in the human genome) was cloned into all 3 lentiviral transfer vectors:

EGFP sgRNA GGGCGAGGAGCTGTTACCG

To clone the sgRNA guide sequence, plasmids were cut and dephosphorylated with FastDigest BsmBI and FastAP (Fermentas) at 37 °C for 2 hours. Oligonucleotides for the EGFP sgRNA guide sequence (Integrated DNA Technologies) were phosphorylated using polynucleotide kinase (Fermentas) at 37 °C for 30 minutes and then annealed by heating to 95 °C for 5 minutes and cooling to 25 °C at 1.5 °C/minute. Using T7 ligase (Enzymatics), annealed oligos were ligated into gel purified vectors (Qiagen) at 25 °C for 5 minutes. Cloned transfer plasmids were amplified using a endotoxin-free midi-prep kit (Qiagen).

To make lentivirus, the transfer plasmids were co-transfected with packaging plasmids pMD2.G and psPAX2 (Addgene plasmids 12259 and 12260), as described previously¹. Briefly, for each virus, a T-75 flask of 80 % confluent HEK293T cells (ATCC CRL-3216) was transfected in OptiMEM (Life Technologies) using 10 ug of the transfer plasmid, 5 ug pMD2.G, 7.5 ug psPAX2, 100 ul of Plus Reagent (Life Technologies), and 50 ul of Lipofectamine 2000 (Life Technologies). After 6 hours, media was changed to D10 media, DMEM (Life Technologies) with 10 % fetal bovine serum (Hyclone), with 1 % bovine serum albumin (Sigma) added to improve virus stability. After 60 hours, viral supernatants were harvested and centrifuged at 3,000 rpm at 4 °C for 10 min to pellet cell debris. The supernatant was filtered through a 0.45 um low protein binding membrane (Millipore) and used immediately.

Lentiviral functional titration. Lentiviruses were titered in a functional assay by measuring puromycin resistance after transduction. All lentiviruses were produced in triplicate transfections. Relative titer measurements from separate viral production transfections performed weeks apart resulted in similar relative titers.

For each viral construct, 2.5×10^4 HEK293T-EGFP cells were transduced in suspension (i.e. during plating) with 10, 100, or 1000 ul of viral supernatant in wells of a 24-well plate. For lentiGuide-Puro transduction the HEK293T-EGFP cells also had a genomically-integrated copy of Cas9 from previous transduction with lentiCas9-Blast. Each transduction condition (construct and virus volume) was performed in triplicate. In each well, D10 culture media was added to make the final volume 1.5 ml. Cells without any virus added were also plated in six wells (3 wells for puromycin treatment, 3 wells as control).

At 24 hours post-transduction, media was changed to D10 with 1 ug/ml puromycin (Sigma) for all wells except the uninfected controls without puromycin. At 3 days post-transduction, cells in all wells were split 1:5 to prevent any well from reaching confluence. Except for the uninfected controls without puromycin, new D10 media was supplemented with 1 ug/ml puromycin. At 5 days post-transduction, all cells in the uninfected control wells treated with puromycin were floating/dead, which was verified using Trypan Blue exclusion (Sigma).

For the remaining wells, adherent cells were present and cell viability was measured using CellTiter Glo (Promega) following the manufacturer's protocol. After allowing cells to reach room temperature, media was aspirated from the cells and CellTiter Glo (diluted 1:1 in phosphate-buffered saline) was added. Plates were covered with foil, placed on an orbital shaker for 2 min, and then incubated for 10 minutes at room temperature. Luminescence was measured on an Synergy H4 plate imager (Biotek) using a 1 second integration time and auto-gain to utilize the full dynamic range of the detector. Positive controls (untransduced cells without puromycin) and negative controls (empty wells) were included in the assay.

Fold differences in titer between viral constructs were calculated using luminescence values. Specifically, comparisons were made between pairs of viruses for the same volume of supernatant. Only viral volumes for which cell survival was greater than 1% and less than 20 % of control (untransduced) cells were directly compared. Assuming Poisson statistics, 20 % cell survival implies that approximately 90 % of cells surviving puromycin selection were infected by only a single virus.

Flow cytometry data was collected from the same set of infections using a BD Accuri C6 flow cytometer. Using FlowJo (TreeStar), single cells were distinguished from debris and doublets by gating in forward and side scatter area plots. EGFP fluorescence was measured in the gated

population from transduced and uninfected HEK293T-EGFP cells. For transductions with lentiGuide-Puro, HEK293T-EGFP cells had been transduced with lentiCas9-Blast and selected for 6 days with 5 ug/ml blasticidin (Life Technologies). For all antibiotic selections (puromycin and blasticidin), uninfected control cells were also exposed to the same concentration and duration of antibiotic selection to verify complete elimination of untransduced cells.

Design of GeCKOv2 libraries. Genome-wide sgRNA libraries for the human and mouse genomes were designed using the following steps:

(1) *Identification of constitutive exons:* For the human library, RNA sequencing data from the Illumina Human Body Map 2.0 (GEO accession number: GSE30611) was mapped to the reference human genome (hg19) using TopHat v1.0.14² and transcripts were reconstructed with Cufflinks v1.0.2³, as previously described⁴. Exons expressed in all tissues in the Human Body Map dataset were termed constitutive and chosen for sgRNA targeting. For the mouse library, we selected exons that are included in all of the NCBI RefSeq (<http://www.ncbi.nlm.nih.gov/refseq/>) transcripts for the same gene.

In both species, for each gene, we excluded the first and last exons and any exon that contained an alternative splicing site. Using these procedures, we chose 4 constitutive exons for each gene. For genes where there were less than 4 constitutive exons, we added exons starting from the second coding exon towards the end of the gene. The coding boundaries for each exon were identified using the NCBI Consensus CoDing Sequence (CCDS) database (<http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi>).

(2) *Choice of sgRNA sequences:* For each gene, all *S. pyogenes* Cas9 sgRNA sequences of the form (N)₂₀NGG in all constitutive exons (from the procedure in (1) above) were selected as candidate targets. Each 20mer candidate target sgRNA was mapped to a precompiled index containing all 20mer sequences in the human genome followed by either NGG or NAG. This mapping was done using the Bowtie short read aligner⁵, allowing up to 3 base mismatches (with parameters -a --best -v 3). For each potential off-target identified by the mapping, the following score was calculated⁶:

$$S_{\text{off-target}} = \prod_{e \in M} (1 - W[e]) \times \frac{1}{\left(\frac{(19-\bar{d})}{19} \times 4 + 1 \right)} \times \frac{1}{n_{mm}^2}$$

Within the first term, M is the set of mismatches between the potential off-target and the candidate target sgRNA. For each mismatch in M , e denotes the position of the mismatch relative to the protospacer-adjacent motif (PAM). The values of e range between 1 (for the most PAM-distal base in the sgRNA) to 20 (for the most PAM-proximal base in the sgRNA). Using e as the index, a value from the look-up table W denotes the empirically-determined weight (relative to the other terms in the $S_{\text{off-target}}$ metric) that penalizes mismatches based on their position in the sgRNA sequence⁶:

e	1	2	3	4	5	6	7	8	9	10
$W[e]$	0	0	0.014	0	0	0.395	0.317	0	0.389	0.079

e	11	12	13	14	15	16	17	18	19	20
$W[e]$	0.445	.508	0.613	0.851	0.732	0.828	0.615	0.804	0.685	0.583

\bar{d} is the mean pairwise distance between all pairs of elements in M and n_{mm} is the number of elements in M .

Each of the individual off-targets ($S_{\text{off-target}}$) for one candidate target sgRNA were integrated into an aggregate off-target score as follows:

$$S_{\text{guide}} = \frac{100}{1 + \sum_{i=1}^n S_{\text{off-target}}(i)}$$

$S_{\text{off-target}}$ is the score for a single potential off-target and S_{guide} is a score (0-100 scale) that provides a rating of how well a candidate sgRNA uniquely targets within the genome.

Candidate sgRNAs with higher values of S_{guide} are predicted to have less off-target activity.

For each gene, we chose 6 sgRNAs with the highest values of S_{guide} across all 4 constitutive exons (from step (1)) subject to constraint that no more than 2 sgRNAs could target a single exon. This procedure resulted in extremely uniform coverage of genes: For 99.4% of genes in the GeCKOv2 human library and 99.8% of genes in the GeCKOv2 mouse library, each gene was targeted with exactly 6 sgRNAs.

(3) *Targeting of mature miRNAs:* For the design of miRNA targeting guides, we used the pre-miRNA sequence coordinates from the mirBASE database (www.mirbase.org)⁷. For each pre-miRNA, we listed all the possible (N)₂₀NGG sequences. In total, we chose up to 4 sgRNAs per miRNA or less if there were not 4 sgRNAs present in the pre-miRNA sequence.

GeCKO library pooled synthesis and cloning. DNA oligonucleotide library synthesis was completed on a programmable microarray using a B3 Synthesizer (CustomArray) and SAFC Proligo reagents (Sigma), as recommended by the manufacturer. The synthesis products were cleaved from the microarray and deprotected by overnight incubation in 28-30% ammonium hydroxide at 65 °C, dried, resuspended in 30 ul TE buffer and then purified using a QIAquick spin column (Qiagen). Full-length oligonucleotides (74 nt) were amplified by PCR using Phusion HS Flex (NEB). For the PCR reaction, the manufacturer's protocol was followed using 0.1 ul of synthesized oligonucleotide template, primers Array F and ArrayR (see below), an annealing temperature of 63 °C, an extension time of 15 s, and 20 cycles. After PCR, the 140 bp amplicon was size-selected using a 2% agarose E-Gel EX (Life Technologies, Qiagen).

ArrayF	TAACTTGAAAGTATTCGATTCTGGCTTATATATCTTGTGGAAAGGAC GAAACACCG
ArrayR	ACTTTTCAAGTTGATAACGGACTAGCCTTATTTAACTTGCTATTCT AGCTCTAAAAC

The vector backbone (lentiCRISPR v2 or lentiGuide-Puro) was digested with BsmBI (Fermentas) and treated with FastAP (Fermentas) at 37°C for 2 hours and gel-purified on a 1 % E-Gel EX (Life Technologies, Qiagen). A 20 ul Gibson ligation reaction (NEB) was performed using 10 ng of the gel-purified inserts and 25 ng of the vector (for lentiCRISPR v2) and using 5 ng of the gel-purified inserts and 25 ng of the vector (for lentiGuide-Puro). From the ligation, 0.5 ul of the reaction was transformed into 25 ul of electrocompetent cells (Lucigen) according to the manufacturer's protocol using a GenePulser (BioRad). To ensure no loss of representation, sufficient parallel transformations were performed using the same ligation reaction and plated onto 245 mm x 245 mm plates (Corning) with carbenicillin selection (50 ug/ml), which yielded

30-200 X library coverage. Colonies were scraped off plates and combined before plasmid DNA extraction using Endotoxin-Free Plasmid Maxiprep (Qiagen).

Library sequencing and validation. To check library representation, synthesis fidelity, and bias, libraries were amplified and then deep sequenced. First, libraries were PCR amplified for 16 cycles using Phusion Flash High-Fidelity (Thermo) with primers to add adaptors for Illumina sequencing. For all libraries, PCR reactions were performed in duplicate and barcoded to allow quantification of bias introduced by PCR. Samples were sequenced on a MiSeq following the manufacturer's protocol using a v3 150 cycle kit with 10% PhiX (Illumina).

PCR replicates were demultiplexed using FASTX-Toolkit (Hannon Lab, CSHL) and adaptors were trimmed using cutadapt to leave only the sgRNA guide sequence⁸. Alignment of the guide sequence to the appropriate GeCKO library index was done using Bowtie with parameters to tolerate up to a single nucleotide mismatch⁵. The Bowtie alignment was then read into Matlab for further analysis (Mathworks). For all libraries, greater than 90 % of sgRNAs were represented with at least one sequencing read and the difference in representation between the 90th and 10th percentile sgRNAs was always less than 15-fold. Histograms of sgRNA distributions and cumulative sgRNA read counts for libraries in both lentiCRISPRv2 and lentiGuide-Puro are shown in Supplementary Figure 2 (human) and Supplementary Figure 3 (mouse).

Vector maps, library sequences and reagent distribution. All lentiCRISPR plasmids and GeCKO libraries are available on Addgene. Please see <http://genome-engineering.org/gecko/> for downloadable vector maps. See labeled sequences in Supplementary Data for more details.

The sgRNAs in the human and mouse v2 GeCKO libraries are available for download on the GeCKO website or from Addgene.

Supplementary Data

LentiCRISPR v2

Pink	BsmBI TypeIIs sites for cloning in 20bp sgRNA guide sequence after removing 1.8kb spacer sequence
Green	+85 chRNA sequence for sgRNA
Gray	EFS promoter sequence
Yellow	Human codon-optimized SpCas9 coding sequence
<i>Italics</i>	FLAG peptide tag
Red	P2A bicistronic linker/self-cleaving peptide
Blue	Puromycin resistance coding sequence

GTCGACGGATCGGGAGATCTCCGATCCCCTATGGTGACTCTCAGTACAATCTGCTTGATGCCGCATAGTTAAGC
CAGTATCTGCTCCCTGCTTGTGTTGGAGGTCGCTGAGTAGTGGCGAGCAAAATTAAAGCTACAACAAGGAAGG
CTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCCTTGCCTGCTCGCATGTACGGGCCAGATATA
CGCGTTGACATTGATTATTGACTAGTTATTAAAGTAATCAATTACGGGTCTTACGGTCAATTAGTTCATAGCCC
TTCCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCCGCAACGACCCCCGCCATTGACGTCAATAAT
GACGTATGTTCCCATAGTAACGCAATAGGACTTCCATTGACGTCAATGGTGGAGTATTTACGGTAAACTGCC
ACTTGGCAGTACATCAAGTGTATCATGCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGG
CATTATGCCAGTACATGACCTTATGGACTTCTACTGGCAGTACATCTACGTATTAGTCATCGCTATTACCAT
GGTGATGCGGTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTCACGGGATTCCAAGTCTCCACCCCA
TTGACGTCAATGGAGTTTGGCACCAAAATCAACGGACTTCCAAATGCGTAACAACCTCCGCCCCATTG
ACGCAAATGGCGGTAGGCCTGACGGTGGAGGTCTATATAAGCAGCGCTTGCCTGACTGGGTCTCTGGT
TAGACCAGATCTGAGCTGGGAGCTCTGGCTAACTAGGAACCCACTGCTTAAGCCTCAATAAGCTTGCCTGA
GTGCTTCAAGTAGTGTGCCCCTGTTGACTCTGTAACTAGAGATCCCTCAGACCTTTAGTCAGTGTG
GAAAATCTCTAGCAGTGGCGCCGAACAGGACTTGAAAGCAGAAGGGAAACCAGAGGAGCTCTCGACGCAGGAC
TCGGCTTGTGAAAGCGCAGCGCACGGCAAGAGGCAGGGCGCAGCTGGTAGTACGCCAAATTTGACTAGCGGAG
GCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAGCAGGGGAGAATTAGATCGCAGGGAAAAATTGG
TTAAGGCCAGGGGAAAGAAAAATATAAATTAAACATATAGTATGGCAAGCAGGGAGCTAGAACGATTGCACT
TAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGACAGCTACAACCCTCATTGTCAGACAGGAT
CAGAAGAACTTAGATCATTATAATACAGTAGCAACCCCTATTGTCAGACAGGATAGAGATAAAAGACACC
AAGGAAGCTTAGACAAGATAGAGGAAGAGCAAACAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTCA
GACCTGGAGGAGGAGATGAGGACAATTGGAGAAGTGAATTATATAAATAAAGTAGTAAAATTGAACCA
GGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTCAGAGAGAAAAAGAGCAGTGGAAATTAGGAGCTTGT
TGGTTCTGGAGCAGCAGGAAGCACTATGGCGCAGCGTCAATGACGCTACGGTACAGGCCAGACAATTATTGT
CTGGTATAGTCAGCAGCAGAACAAATTGCTGAGGGCTATTGAGGCCAACAGCATCTGTCAGACTCACAGTCTGG
GGCATCAAGCAGCTCCAGGCAAGAACCTGGCTGTGGAAAGATACTAAAGGATCAACAGCTCTGGGATTGGGG
TTGCTCTGGAAACTCATTGACCAACTGCTGTGCCTTGAATGCTAGTTGGAGTAATAAAATCTGGAACAGATT
GGAATCACACGACCTGGATGGAGTGGACAGAGAAATTACAATTACACAAGCTTAACACTCCTTAATTGAAGAA
TCGCAAACACAGCAAGAAAAGAATGAACAAGAATTATGGAATTAGATAATGGCAAGTTGTGAATTGGTTAA
CATAAACAAATTGGCTGTGGTATATAAATTATCATAATGATAGTAGGAGGCTGGTAGGTTAAAGAATAGTTTG
CTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATTACCAATTATGTTCAAGACCCACCTCCAACCCGAGG
GGACCCGACAGGCCGAAGGAATAGAAGAAGAGTGGAGAGAGACAGAGACAGATCCATTGATTAGTGAACGG
ATCGGCACTGCGTGCAGCAATTCTGAGACAAATGGCAGTATTCCATCCACAATTAAAAGAAAAGGGGGATTGGG
GGGTACAGTGCAGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAACAATTAC
AAAAATTCAAATTTGGGTTATTACAGGGACAGCAGAGATCCAGTTGGTTAAATTAGGTACCGAGGGCCTATT
TCCCATGATTCTCATATTGCAATACGATAACAGCTGTTAGAGAGATAATTAGAATTAAATTGACTGTAAACA
CAAAGATATTAGTACAAATACGTGACGTAGAAAGTAATAATTCTGGTAGTTGCAGTTAAAATTATGTTT
AAAATGGACTATCATATGCTTACCGTAACCTGAAAGTATTCGATTCTGCTTATATATCTGTGAAAGGACG
AAACACCG**GAGACG**GTGTAATGAGCACACAAATACATGCTAAATATTATATTCTATGACCTTATAAAATC
ACCAAAATCTCTTTAATAACTTGTAGTATCAATAATTAGAATTGGTTATGTTCTTCACTTAAATAAGCTACTCC
AATGAGCAAAATAAAAAACGCTAGTTAGTAACTCGCCTGTTCTCACTTAAATAAGCTACTCC
TTGTTCTAAGCGGTAGCTCTGCTTCAATCATTGGTGGAGCATCTTCAATGTTCTAACCTC
ACTAAAGCATTGTCTTAACAATGACTTCATTAGTTAACATCTTCAATGTTGACCTGACCTGATTGGAAAATCCTGT

TGATGTTAACAAATTCTAATCCAGCTCAACAGCTATTCACAAGCTTATGATTCTTCTTGTAAATAAAC
AATTTCCATAATACATTAAACAACATGTGATCCAGCTGCTTTTACAGCTTATGCTTCTAAACTAATTCA
TAATTTGTCTTTAATGCACCAATATTAATACCATATCAATTCTGTTGCACCATCTTAATTGCTCAGAAC
TTCGAATGCTTTGAGCTGTTGCATGCACCTAGAGGAAACCTACAACATTGTTATTCTACATTGTCCT
TTAATAATTCTTACAATAGCTGTTCAATATGAATTAAACACAAACTGTTGAAAATCAAATTCAATTGCTC
CATATTGTTAATTCACTTCAAGCTTCTGAGCATCTTGTAAATAATGTTGATCTATATATTGTTAGTT
TTCTCCTATATATTCACTTTAATTAAATTCTTAATTTCGCTACTTTAACCTTAGCGTTGAACAGATT
ACCAACACCTATAAAATAATTAGTTAGGTTCACTGGCGAACAGCAAATCATGACTTATCTCT
AATAAAATTAGTAAGTCTGTCCTGGCATATTACATTACATCGATGTAAGTCTAACATTAAACACTTAAAGT
CCAGCAATTGAGTTAGGGTGTGCTCTCAATGATTCAATTAGTTCAATTAAATTCTTTAATTCTCTGGTT
AAAATTCAAGTTAAAGTGAAGGTGAAATATGCACCCATTCTTAATAAAATCTCTAAATAGTCTACTAATGTT
TATTTGTTTTAATAAAATCAAGCAGCCTGCTATTAAATAGAGCTTGATTCCATCTTATCTCTAGTGAG
TCATCAATTACATACATACTTCTCATAGCAAAACAAATTAAATCCGTTATCTCTTCTTAGCAATT
TCTACCCATTCACTTAAATCCAGTTAAAGTTTACAATATTAAACTCCATTCTTCACTGAGCGATTCTAC
AACACTTGTACAAACTGAAATATAGAGCCGATTTTGAATGCTATTAAAGCCTTAAAGGATAATT
CAATCAATTAAATTGGCCTGTTGATTCCATCTAACATTACAAATGACCATCATGTTTATTGCCATT
TCTGTCAGCATCTGGTCATTCTAATAAAATCTGATCATGTTAATACCATATTCAAGCGTATTTCATG
CAGGATCAAATTCTGGATTGATTACAACATTAAATGTTCATCTCAATGCTCTAACCTCAATA
ACGTTATATCTGATTACGTAAATTGGGTAATTAGTTCTGTTCAATTACTGCGTAAAGGATAATT
TAAATCTTTTAGCTCTTGCTTTTGTACGTCTCTGTTAGAGCTAGAAATAGCAAGTAAATAAGGCTA
GTCGTTATCAACTGAAAAGTGGACCGAGTCGGTGCTTTTTGAAATTGCTAGCTAGGTCTGAAAGGAGTGG
AATTGGCTCCGGTCCCCGTAGTGGCAGAGCGCACATGCCACAGTCCCCGAGAAAGTGGGGGAGGGGTCGGCA
ATTGATCCGGTGCCTAGAGAAGGTGGCGGGGTTAAACTGGAAAGTGATGTCGTGACTGGCTCCGCTTT
GAGGGTGGGGAGAACCGTATATAAGTGCAGTAGTCGGCGTGAACGTTCTTCTGCAACGGTTGCGCCAGAAC
ACAGGACCGTTAGAGCGCTGCCACATGGACAAGAAGTACAGCATGGCTGGACATGGCACCAACTCTG
GCTGGGCCGTGATCACCGACGAGTACAAGGTGCCAGAAGAAATTCAAGGTGCTGGCAACACCGACCGCACAGC
ATCAAGAAGAACCTGATCGGAGCCTGCTGTTGACAGCGGGAAACAGCGAGGCCACCCGGCTGAAGAGAACCGC
CAGAAGAAGATAACCCAGACGGAGAACCGGATCTGCTATCTGCAAGAGATCTCAGCAACGAGATGCCAAGGTGG
ACGACAGCTCTTCCACAGACTGGAAGAGTCTCTCTGGTGGAGAGGATAAGAAGCAGCGAGGCCACCCATCTC
GGCAACATCGTGGACGAGGTGGCTTACACAGAGAAGTACCCACCATCTACCACCTGAGAAAGAAACTGGTGACAG
CACCGACAAGGCCGACTCGGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTCCGGGCCACTCCTGATCG
AGGGCGACCTGAACCCGACAACAGCAGCTGGACAAGCTGTTCATCCAGCTGGTGAGACCTACAACCAGCTGTT
GAGGAAAACCCATCAACGCCAGCGGTGACGCCAGGCCATCTGCTGCCAGACTGAGCAAGAGCAGACGGCT
GGAAAATCTGATGCCAGCTGCCGGCGAGAAGAAGATGCCCTGTTGGAAACCTGATTGCCCTGAGCCTGGGCC
TGACCCCCAACTCAAGAGCAACTCGACCTGGCGAGGATGCCAAACTGAGCTGAGCAAGGACACCTACGAC
GACCTGGACAACCTGCTGGCCAGATCGCGACCAAGTACGCCACCTGTTCTGGCCGCAAGAACCTGTCGACGC
CATCCTGCTGAGCGACATCTGAGAGTGAACACCGAGATACCAAGGCCCCCTGAGCGCCTCTATGATCAAGAGAT
ACGACGAGCACCAACCGGACCTGACCCCTGCTGAAAGCTCTGAGCAGCTGCCTGAGAAGTACAAAGAGATT
TTCTCGACAGAGCAAGAACGGTACGCCGGCTACATTGACGGGGAGCCAGGAAGAGTTCTACAAGTT
CAAGCCCACCTGAAAAGATGGACGGCACCGAGGAAGTCTGTAAGCTGAACAGAGAGGACCTGCTGGAAGC
AGCGGACCTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGAGAGCTGACGCCATTCTGCGCGGCCAGGAA
GATTTTACCCATTCTGAAGGACAACCGGAAAAGATCGAGAAGATCTGACCTTCCGATCCCCACTACGTGG
CCCTCTGGCCAGGGAAACAGCAGATTGCTGGATGACCGAGAAAGAGCGAGGAACCATCCCCCTGGAACCTCG
AGGAAGTGGTGGACAAGGGCGCTCCGCCAGAGCTTATCGAGCGGATGACCAACTTCGATAAGAACCTGCCAAC
GAGAAGGTGCTGCCAAGCACGCGCTGCTGAGACTTACCGTGATAACGAGCTGACCAAGTGAAGAAC
GACCGAGGGAAATGAGAAAGGCCGCTTCTGAGCGGGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCA
ACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTCAAGAAATCGAGTGCTCGACTCCGTGGAAATCTCC
GGCGTGGAAAGATCGGTTCAACGCCCTCCCTGGCACATACCACGATCTGCTGAAATTATCAAGGACAAGGACT
GGACAATGAGGAAAACGAGGACATTCTGGAAGATATGTCGACCTGACACTGTTGAGGACAGAGAGATGATCG
AGGAACGGCTGAAAACCTATGCCACCTGTTGACGACAAAGTGATGAAGCAGCTGAGCGGGAGATAACCGGC
TGGGGCAGGGTGAAGCCGAAGCTGATCAACGGCATCGGGACAAGCAGTCGGCAAGACAATCTGGATTCTGAA
GTCGACGGCTCGCCACAGAAACTTCTGACGCTGATCCACGACAGCAGCTGACCTTAAAGAGGGACATCCAGA
AAGCCCAGGTGTCGGGCCAGGGCGATAGCCTGACGAGCACATTGCAATCTGGCCGGAGCCCCGCCATTAAGAAG
GGCATCCTGACAGACTGAGAGGAGAACCCAGAAGGGACAGAAGAACAGCCGAGAGAATGAAGCGGATGAAAGG
GCAATGAGGACTGGGAGCCAGATCTGAAAGAACACCCCGTGAAGAACACCCAGTGCAGAACGAGAAGCTG
CTGACTACCTGACGAAATGGCGGGATATGACGTGGACCGAGGAACCTGGACATCAACGGCTGTCGACTACGATGT

TAGTATAATACGACAAGGTGAGGAAC TAAACC ATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTACCGCGCGAC
GTCGCCGGAGCGGTGAGTTCTGACCGACCGGCTCGGGTCTCCGGGACTTCGTGGAGGACGACTTCGCCGGTGT
GGTCCGGGACGACGTGACCTGTTCATCAGCGCGTCAAGGACAGGTGGTCCGGAGGTCTGACGAACTCCGGGACGCCCTGGCCTGGGTGT
GGGTGCGCGGCCTGGACGAGCTGTACGCCGAGTGGTCCGGAGGTCTGACGAACTCCGGGACGCCCTGGCCTGGGCG
GCCATGACCGAGATCGCGAGCAGCCGTGGGGCGGGAGTTGCCCTGCGCACCCGGGCAACTGCGTGCACCT
CGTGGCGAGGAGCAGGACTGACACGTCTACGAGATTGATTCACCGCCCTTCTATGAAAGGTTGGGTTCG
GAATCGTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTTCGCCAACCCAAAC
TTGTTATTGCA GCTTATAATGGT TACAAATAAGCAATAGCATCAAATTCAAAATAAGCATTTC
GCATTCTAGTTGTGGTTGTCAAAC TCAATGTATCTTATCATGCTGTATACCGTCACCTAGCTAGAGCT
TGGCGTAATCATGGTCA TAGCTGTTCTGTGAAATTGTTATCGCTCACAA TTCCACACACATAGAGCGGA
AGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGA GCTA ACTCACATTAAATTGCGTGCCTCACTGCCCGCTT
CCAGTCGGGAAACCTGCGTGCAGCTGCATTAATGAATCGGCCAACCGCGGGGAGAGGGCGGTTGCGTATTGGG
GCTCTTCCGCTTCTCGCTCACTGACTCGCTGCCCTGGCTGGCTGCCGAGCGGTATCAGCTCACTCAAAG
GCGGTAAACCGTTATCCACAGAACGAGGATAACCGAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAG
GAACCGTAAAAGGCCGCGTTGCTGGCTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCT
CAAGTCAGAGGTGGCGAACCCGACAGGACTATAAAGATA ACCAGGC GTTCCCCCTGGAAAGGCTCCCTGCGCTCT
CCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCGCCCTTCTCCCTTCCGGAAAGCGTGGCGCTTCTCATAGCTC
ACGCTGTAGGTATCTCAGTTCGGTAGGTCGTTGCTCCAGCTGGCTGTGCA CGAACCCCCCGTTAGCCCG
ACCGCTGCCCTTATCCGTA ACTATCGTCTTGAGTCCAACCGCTAAGACGACTTATGCCACTGGCAGCAGCC
ACTGGTAACAGGATTAGCAGAGCGAGGTATGAGCGGTCTACAGAGTTCTGAAGTGGTGGCTA ACTACGGCTA
CACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTCGGAAAAGAGTTGGTAGCTCTTGAT
CCGGCAAAACAAACCACCGCTGGTAGCGGTGTTTTGCAAGCAGCAGATTACCGCAGAAAAAAAGGATCT
CAAGAAGATCCTTGATCTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTGGTCA
GAGATTATCAAAAGGATCTTACCTAGATCCTTAAATTAAAATGAAGTTAAATCAATCTAAAGTATATATG
AGTAAACTTGGTCTGACAGTTACCAATGCTTAACTCAGTGAGGCACCTATCTAGCGATCTGTCTATTCGTTCATCC
ATAGTTGCGTCACTCCCCTGCTGTTAGATAACTACGATACGGGAGGGCTTACCATCTGCCCTAGTGCTGCAATGAT
ACCGCGAGACCCACGCTCACCGGCTCCAGATTATCAGCAATAAACCGCCAGCGGAAGGGCGAGCGCAGAAGTG
GTCCTGCAACTTATCCGCTCCATCCAGTCTATTAAATTGTTGCCGGAAAGCTAGAGTAAGTAGTTGCGCCAGTTAAT
AGTTGCGAACGTTGGCATTGCTACAGGCATCGGGTGTACGCTCGTGTGTTGGTATGGCTTCACTCAGCTC
CGGTTCCCAACGATCAAGGCAGTTACATGATCCCCATGTTGCAAAAAGCGGTTAGCTCCTTGGTCCCTCGA
TCGTTGTCAGAACGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTTACTGTCATG
CCATCCGTAAGATGTTCTGTGACTGGTAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGCGACCGAG
TTGCTCTTGGCCGGCGTCAATACGGGATAATACCGGCCACATAGCAGAACCTTAAAGTGTCTCATCTGGAAAAC
GTTCTTGGGGCGAAAACCTCAAGGATCTTACCGCTGTTGAGATCCAGTTGATGTAACCCACTGTGCACCCAAAC
TGATCTTCA GCATCTTTACTTCA CCGCGTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGAAAAAGGG
ATAAGGGCAGACGGAAATGTTGAATACTCATACTCTTCTTTCAATATTATTGAAGCATTATCAGGGTTATT
GTCTCATGAGCGGATACATATTGAATGTATTAGAAAATAACAAATAGGGTTCCGCGCACATTCCCCGAAAA
GTGCCACCTGAC

lentiCas9-Blast

Gray	EFS promoter sequence
Yellow	Human codon-optimized SpCas9 coding sequence
<i>Italics</i>	FLAG peptide tag
Red	P2A bicistronic linker/self-cleaving peptide
Blue	Blast resistance coding sequence

GTCGACGGATCGGGAGATCTCCGATCCCCTATGGTCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAC
CAGTATCTGCTCCCTGCTTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAATTTAACGCTACAACAAGGAAGG
CTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCCTTGCCTGCTCGCATGTAACGGGCCAGATATA
CGCGTTGACATTGATTATTGACTAGTTATTAAAGTAATCAATTACGGGTCTTACGGTACAGCTCATAGCCATATATGGAG
TTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACGCCAACGACCCCCGCCATTGACGTCAATAAT
GACGTATGTTCCCATAGTAACGCCAATAGGACTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCC
ACTTGGCAGTACATCAAGTGTATCATGCCAAGTACGCCCTATTGACGTCAATGACGGTAAATGGCCGCCCTGG
CATTATGCCAGTACATGACCTTATGGACTTCTACTTGGCAGTACATCTACGTATTAGTCATGCTATTACCAT
GGTGATGCGGTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTCACGGGATTCCAAGTCTCACCCCC
TTGACGTCAATGGGAGTTGTTGGCACC AAAATCAACGGGACTTCCAAAATGCGTAACAACCTCCGCCATTG
ACGCAAATGGCGGTAGGCCTGACGGTGGGAGGTCTATATAAGCAGCGCTTGCCTGACTGGGTCTCTGGT
TAGACCAGATCTGAGCCTGGGAGCTCTGGCTAACTAGGAAACCCACTGCTTAAGCCTCAATAAGCTTGCCTTGA
GTGCTTCAAGTAGTGTGCGCCGCTGTGACTCTGGTAACTAGAGATCCCTCAGACCCCTTACTAGTGTG
GAAAATCTCTAGCAGTGGCGCCGAACAGGGACTTGAAAGCAGAAGGGAAACCAGAGGAGCTCTCGACGCAGGAC
TCGGCTGCTGAAGCGCGCACGCCAAGAGGCCAGGGCGACTGGTGGAGTACGCCAAAATTTGACTAGGGAG
GCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTTAACGCGGGGAGAATTAGATCGCAGTGGAAAAATTCCGG
TTAAGGCCAGGGGAAAGAAAAATATAAATTAAACATATAGTATGGCAAGCAGGGAGCTAGAACGATTGCAAGT
TAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGACAGCTACAACCATTCCAGACAGGAT
CAGAAGAACTTAGATCATTATAATACAGTAGCAACCCCTATTGTTGCAATCAAAGGATAGAGATAAAAGACACC
AAGGAAGCTTAGACAAGATAGAGGAAGAGCAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTCA
GACCTGGAGGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAGTAGTAAAATTGAACCATT
GGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAGAGCAGTGGGAAATTGGAGCTTGGC
TGGGTTCTGGGAGCAGCAGGAAGCACTATGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGT
CTGGTATAGTCAGCAGCAGAACAAATTGCTGAGGGCTATTGAGGCAGAACAGCATCTTGCACACTCACAGTCTGG
GGCATCAAGCAGCTCCAGGCAAGAACCTGGCTGTGGAAAGATACCTAAAGAGTCAACAGCTCTGGGATTGGGG
TTGCTCTGGAAAATCTTGACCAACTGCTGTGCTTGGAAATGCTAGTTGGAGTAATAAATCTGGAACAGATT
GGAATCACACGACCTGGATGGAGTGGACAGAGAAATTACAATTACACAAGCTTAATACACTCTTAATTGAAGAA
TCGCAAACACAGCAAGAAAAGAATGAACAAGAATTATTGAATTAGATAAAATGGCAAGTTGTGGAAATTGGTTAA
CATAAACAAATTGGCTGTGGTATATAAATTATTCTATAATGATAGTAGGAGGCTGGTAGGTTAAGAATAGTTTG
CTGTACTTTCTATAGTAATAGAGTTAGGCAGGGATATTCACTTACGTTACAGGCCACCTCCAACCCCGAGG
GGACCCGACAGGCCGAAGGAATAGAAGAAGAGTGGAGAGAGAGACAGAGACAGATCCATTGATTAGTGAACGG
ATCGGCACCTGCGCCATTCTGCAGACAAATGGCAGTATTCACTCCACAATTAAAAGAAAAGGGGGATTGGG
GGGTACAGTCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAACAAACTAAAGAATTACAAAACAAATTAC
AAAAATTCAAATTTGGGTTATTACAGGGACAGCAGAGATCCAGTTGGTTAATTAGCTAGTAGGTCTTGAA
AGGAGTGGGAAATTGGCTCCGGTGGCGTCAGTGGCAGAGCGCACATGCCAACAGTCCCCGAGAAGTTGGGGGAG
GGGTGGCAATTGATCGGTGCTTAGAGAAGGTGGCGGGTAAACTGGGAAAGTGTGCTGTACTGGCTCCGC
CTTTTCCGAGGGTGGGGAGAACGTATATAAGTGCAGTAGTCGCCGTGAAACGTTTTGGCAACGGGTTGC
CGCCAGAACACAGGACCGTTAGAGCGCTGCCACCATGGACAAGAAGTACAGCATGGCCTGGACATGGCACCA
ACTCTGTGGCTGGCGTGATCACCGACGAGTACAAGGTGCCAGCAAGAAATTCAAGGTGCTGGCAACACCGAC
CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTTGCACAGCGGCAACAGCCGAGGCCACCGCTGAA
GAGAACCGCCAGAAGAAGATACCCAGACGGAAGAACGGATCTGCTATCTGCAAGAGATCTCAGCAACGAGATGG
CCAAGGTGGACGACAGCTTCCACAGACTGGAGAGTCCTCTGGAGAGGATAAGAAGCACGAGCGGAC
CCCACATTGGCAACATCGTGGACGAGGTGGCTACACAGAGAACGGATCTGCTATCTGCAAGAGATCTCAGCAACGAGATGG
GGTGGACAGCAGCAAGGCCGACCTGCGCTGATCTATCTGGCCCTGGCCACATGATCAAGTTCCGGGGCACT
TCCTGATCGAGGGCGACCTGAACCCGACAACAGCAGCGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAAC
CAGCTGTTGAGGAAAACCCATCAACGCCAGCGTGGACGCCAAGGCCATCTGCTGTGCCAGACTGAGCAAGAG
CAGACGGCTGAAAATCTGATGCCAGCTGCCGGCAGAAGAAGAATGGCCTGTTGGAAACCTGATTGCCCTGA
GCCCTGGGCTGACCCCCAACTTCAAGAGCAACTTGCACCTGGCCAGGATGCCAAACTGCAGCTGAGCAAGGACACC
TACGACGACGACCTGGACAACCTGCTGGCCAGATGCCGACCAAGTACGCCACCTGTTCTGGCCGCCAACCT

GTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCCTCTATGA
TCAAGAGATACGACGAGCACCACCAAGGACCTGACCCCTGCTGAAAGCTCTGCGGCAGCAGCTGCCAGAAGACTAC
AAAGAGATTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCAGGAAGAGTTCTA
CAAGTTCATCAAGCCCACCTGGAAAAGATGGACGGCACCAGAGAAGCTGCTGTGAAGCTGAACAGAGAGGACCTGC
TGCGGAAGCAGCGGACCTCGACAACGGCAGCATTCCCCACCAAGATCCACCTGGGAGAGCTGACGCCATTCTCGG
CGGCAGGAAGATTTTACCCATTCTGAAGGACAACCGGGAAAAGATCGAGAAGAGCTGACCTCCGCATCCCCCTA
CTACGTGGGCCCTCTGCCAGGGAAAACAGCAGATTGCCCTGGATGACCAGAAAAGAGCAGGGAAACCATCACCCCT
GGAACCTCGAGGAAGTGGTGGACAAGGGCGCTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTCGATAAGAAC
CTGCCCAACGAGAAGGTGCTGCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGATAACGAGCTGACCAAAGT
GAAATACGTGACCGAGGAATGAGAAAGCCGCTTCTGAGCGCGAGCAGAAAAAGCCATCGTGACCTGCTGT
TCAAGACCAACCGGAAAGTACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGATGCTTGACTCCGTG
GAAATCTCCGGCGTGGAAAGATCGTTCAACGCCCTCCCTGGGACATACACGATCTGTAAGAAATTATCAAGGACAA
GGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGAAAGATATCGTGTGACCTGACACTGTTGAGGACAGAG
AGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTCGACGACAAGTGTGAGCAGCTGAAAGCGGCGGAGA
TACACCGGCTGGGGCAGGCTGAGCCGAAGCTGATCAACGGCATCCGGACAAGCAGTCCGGCAAGACAATCTGGA
TTCTGTAAGTCCGACGGCTCGCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTAAAGAGG
ACATCCAGAAAGCCCAGGTGTCGGCCAGGGCGATAGCCTGACAGCACATTGCCAATCTGGCCGGCAGCCCCGCC
ATTAAGAAGGGCATCTGACAGACAGTGAAGTGGTGGACGAGCTGTGAAAGTGTGACCTGAGGAGCTGTTGAGGACAGAG
CATCGTGTGAAATGCCAGAGAGAACGACCAACCCAGAAGGGACAGAAGAACAGCCCGAGAGAACATGAGCGGA
TCGAAGAGGGCATCAAAGAGCTGGGAGCCAGATCTGAAAGAACACCCCTGGAAAACACCCAGCTGAGAACAG
AAGCTGTACCTGACTACCTGAGAATGGGGGGATATGTACGTGGACCAGGAACCTGGACATCAACCGGCTGTCGA
CTACGATGTGGACCATATCGCCTCAGAGCTTCTGAAAGGACGACTCCATCGACAACAAGGTGCTGACAGAACAGC
ACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCGAAGAGGTGTAAGAACAGATGAAAGAACACTGGCGGAGCTG
CTGACGCCAGCTGATTACCCAGAGAAAGTTGACAAATCTGACCAAGGCCAGAGGAGCTGAGCGAACACTGG
TAAGGCCGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCTGGACTCCC
GGATGAACACTAAGTACGACGAGAAATGACAAGCTGATCCGGAAAGTGTGACCTGAAAGTGTGACCTGAAAGTCAAGCTGGT
TCCGATTTCGGAAGGATTCCAGTTTACAAAGTGCAGAGATCAACAACTACCCACGCCACGACGCCACCT
GAACGCCGCTGTTGGAACCGCCCTGATCAAAAGTACCCCTAAGCTGGAAAGGGAGTTCTGTAACGGGACTACAAGG
TGTACGACGTGCGGAAGATGATGCCAAGAGCGAGCAGGAAATGGCAAGGCTACCGCAAGTACTTCTTACAGC
AACATCATGAACTTTCAAGACCGAGATTACCCCTGGCAACGGGAGATCCGGAGACGGGGCTCTGATCGAGAACAA
CGGCGAACACGGGGAGATCGTGTGGATAAGGGCCGGATTGGCCACCGTGCAGGAAAGTGTGAGCATGCCCAAG
TGAATATCGTAAAAAGACCGAGGTGAGACAGACAGGCCAGCTCAGCAAAGAGTCTACCTGCCAACAGAGAACAGC
AAGCTGATGCCAGAAAGAAGGACTGGGACCTAAGAAGTACGGGGCTTCAGCACAGCCCCACCGTGGCTTACCT
GCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGGTGCTGGGATCACC
TGAAGAAGCAGCTCGAGAAGAACATCGACTTCTGGAAGCCAAGGGCTACAAAGAACAGTGAAGAACAGGAC
ATCATCAAGCTGCTAAGTACTCCCTGTTGAGCTGGAAAACGGCCGGAGAGAACATGCTGGCTCTGCCGGCAACT
GCAGAAGGGAAACGAACTGCCCTGCCCTCAAATATGTGAACTTCTGTACCTGGCCAGCCACTATGAGAACG
AGGGCTCCCCGAGGATAATGAGCAGAAACAGCTGTTGTGAAACAGCACAAGCACTACCTGGACGAGATCATCG
CAGATCAGCGAGTTCTCAAGAGAGTGTGATCTGCCAGCCTAATCTGGACAAAGTGCTGTCCGCTACAACAAGCA
CCGGGATAAGCCATCAGAGAGCAGGCCAGAATATCATCCACCTGTTACCCCTGACCAATCTGGAGCCCCCTGCC
CCTCAAGTACTTGTACACCACCATCGACGGGAAGAGGTACACCGACCAAAAGAGGTGCTGGACGCCACCTGATC
CACCAAGACATCACCGCCCTGTACGAGACACGGATCGACCTGTCAGCTGGAGGGGACAAGCGACCTGCC
AAAGAAGGCTGGACAGGCTAAGAACAGAAAGATTACAAAGACGATGACGATAAGGGATCCGGCAACAAACTTCT
CTCTGCTGAAACAAGCCGGAGATGTCAGAGAGAACATCCCTGGACCGATGGCAAGCCTTGTCTAAGAACAG
CTCATTGAAAGAGCAACGGCTACAATCAACAGCATCCCCATCTGAAAGACTACAGCGTCGCCAGCGCAGCTCTC
TAGCGACGGCGCATCTTCACTGGTGTCAATGTATATCATTTACTGGGGACCTGTGCAAGACTCGTGGTGT
GCACTGCTGCTGCCAGCTGGCAACCTGACTTGATCGTCGACGACTCCCTGGGACTAAAGCCATAGTGAAGG
AGACTGATGGCTGCTGCCAGCTGGGATTTCGTGAAATTGCTGCCCTGGTTATGTTGGAGGGCTAACG
TGATAATCAACCTCTGATTACAAATTGTGAAAGATTGACTGGTATTCTTAACATGTTGCTCTTACGCT
TGTGGATACGCTGCTTAAATGCCCTTGTATCATGCTATTGCTTCCGTATGGCTTCTTCAAGAACAG
ATCCCTGGTTGCTGCTCTTATGAGGAGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTGCT
ACGCAACCCCCACTGGTGGGGCATTGCCACCCACCTGTCAGCTCCCTGGGACTTTGCTTCC
GCCACGGCGAACACTCATGCCGCTGCCCTGGCTGCTGGACAGGGGCTGGCTGTTGGGACTGACA
GGTGTGCGGGAAATCATGTCCTTCCCTGGCTGCTGCCCTGGATTCTGCGCGGGACGTCT
TCTGCTACGTCCTTCCGCCCCCTCAATCCAGCGAACCTCCCTCCGCGGCCCTGCTGCC
CGTCTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTGGGCCCTCCCCGATCGATACCGT
GACCTCGAGA

CCTAGAAAACATGGAGCAATACAAGTAGCAATACAGCAGCTACCAATGCTGATTGTGCCTGGCTAGAAGCACAAG
AGGAGGAGGAGGTGGTTTCCAGTCACACCTCAGGTACCTTAAGACCAATGACTTACAAGGAGCTGTAGATCTT
AGCCACTTTTAAAGAAAAGGGGGACTGGAAGGGCTAATTCACTCCAACGAAGACAAGATATCCTGATCTGT
GATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGCCAGGGATCAGATATCCACTGACCT
TTGGATGGTGTACAAGCTAGTACCAAGTGTGAGCAAGAGAAGGTTAGAAGAAGCCAATGAAGGAGAGAACACCCGCTTG
TTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTATTAGAGTGGAGGTTGACAGCCGCTAGC
ATTTCATCACATGGCCCGAGAGCTGCATCCGGACTGTACTGGGTCTCTGTGTTAGACAGATCTGAGCCTGGGAGC
TCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAGCCTTGAGTGTCTCAAGTAGTGTGTGCCGT
CTGTTGTGTACTCTGTTACTAGAGATCCTCAGACCCCTTGTAGTCAGTGTGGAAAATCTCTAGCAGGGCCCGTT
AAACCCGCTGATCAGCCTGACTGTGCTTCTAGTTGCCAGCCATCTGTTGTTGCCCTCCCCGTGCTTCTTG
ACCCCTGGAAGGTGCCACTCCCCTGTCCTTCTTAATAAAATGAGGAAATTGCATCGCATTGTCAGTAGGTGTCA
TTCTATTCTGGGGGGTGGGTGGGAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGATGCTGGGATG
CGGTGGGCTCTATGGCTTCTGAGGGCGAAAGAACCGAGCTGGGCTCTAGGGGTATCCCACGCCCTGTAGCGGC
GCATTAAGCGCGCGGGTGTGGTGGTACGGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCGCTCCCTT
CGCTTCTCCCTTCTCGCCACGTTGCCGGCTTCCCCGTCAAGCTCTAAATCGGGGCTCCCTTAGGGT
TCCGATTTAGTGTCTTACGGCACCTGACCCAAAAACTTGATTAGGGTGTGTTACGTAGTGGCCATCGCC
TGATAGACGTTTCGCCCTTGACGTTGAGTCCACGTTCTTAATAGTGGACTCTTGTCTCAAACCTGGAACAC
ACTCAACCCATCTCGTCTATTCTTTGATTATAAGGGATTGCGATTTCGGCCTATTGGTAAAAAAATGAGC
TGATTAACAAAAATTAAACGCAATTAAATTCTGTTGAGTGTGTCAGTTAGGTGTGGAAAGTCCCAGGCTCC
CAGCAGGAGTATGCAAAGCATGCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCAGGCTCCAGCA
GGCAGAAGTATGCAAAGCATGCTCAATTAGTCAGCAACCAGTCCCAGGCTTAACCTCGCCATCCCAGGCT
AACTCCGCCAGTCCGCCATTCTCCGCCATTGGCTGACTAATTCTTATTATGCAAGAGGGCAGGCCGCT
CTGCTCTGAGCTATTCCAGAAGTAGTGTGAGGGCTTTGGAGGGCTAGGCTTTGCAAAAGCTCCGGAGCT
TGTATATCATTTCGATCTGACGACGTGTTGACAATTATCATGGCATAGTATATCGGATAGTATAATAC
GACAAGGTGAGGAACCTAACCATGGCAAGTTGACCAAGTGTGCGCTCCGGTGTCTACCGCGCGACGTCGCC
GGTCGAGTTCTGGACCGACCGGCTCGGGTCTCCGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCCGGACG
ACGTGACCTGTTCATCGCGCGTCCAGGACCAAGGGTGTGTCACGAAACACCCCTGGCTGGGTGTGGTGC
CTGGACGAGCTGTACGGCGAGTGGTGGAGGTGTGTCACGAAACTCCGGACGCCCTGGGGCCATGACCGA
GATCGCGAGCAGCCGGGGGGAGTTGCCCTGGCGACCCGGCCGAACTGCGTGCACTTCGTGGCCAGG
AGCAGGACTGACACGTGCTACGAGATTTCGATTCCACCGCCCTTCTATGAAAGGTTGGGCTTCGGAATGTTTC
CGGGACGCCGGCTGGATGATCTCCAGCGCGGGGATCTCATGCTGGAGTTCTGCCACCCAACTGTTATTGC
AGCTTATAATGGTACAATAAGCAATAGCATACAAATTACAATAAGCATTTCAGTCATTCTAGTT
GTGGTTGTCCTAAACTCATCAATGTATCTTATCATGTCAGTCACCTCTAGCTAGAGCTTGGCGTAATCA
TGGTCACTAGCTGTTCTGTGAAATTGTTATCCGCTCACATTCCACACATACGAGCCGAAAGCATAAGTG
TAAAGCCTGGGTGCTTAATGAGTGTGAGCTAATCACATTGCGTGTGCGTACTGCCGCTTCCAGTC
ACCTGTCGTGCCAGTCATTAATGAAATGCCAACCGCGGGAGAGGCGGTTGCGTATTGGCGCTTCCG
TCCTCGCTACTGACTCGCTCGCGTCTGGCTGCGCGAGCGGTATCAGCTCACTCAAAGGCGTAATACG
GTTATCCACAGAATCAGGGATAACGCAAGGAAAGAACATGTGAGGAAAGGCCAGCAAAAGGCCAGGAAC
AGGCCGCGTTGCTGGCTTTCTAGGCTCCGCCCTGACGAGCATCACAAATGACGCTCAAGTCAGAGG
TGGCGAAACCGACAGGACTATAAGATACCGGTTCCCGTGGAGCTCCCTGCGTCTCGTGTGCG
CCTGCCGCTTACCGGATACCTGTCGCCCTTCTCCCTGGAGCGTGGCGCTTCTCATAGCTACGCTGT
ATCTCAGTCCGGTGTAGGTGTCGCTCCAGCTGGCTGTGTCACGAACCCCCCGTTCA
TTATCCGGTAACTATCGTCTTGAGTCAACCCGGTAAGACACGACTATGCCACTGGCAGCAGCACTGGTAACAG
GATTAGCAGAGCGAGGTATGTAGGCCTGCTACAGAGTTCTGAAGTGGTGGCTAACTACGGCTACACTAGAAGAA
CAGTATTGGAATCTGCCTCTGCTGAAGCCAGTTACCTCGGAAAAGAGTTGGTAGCTTGTATCCGG
ACCACCGCTGGTAGCGGTGGTTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTAAGAAGATCC
TTGATCTTCTACGGGTCTGACGCTAGTGGACAAAACACGTTAAGGGATTGGTGTGAGATTCAA
AAAGGATCTCACCTAGATCTTTAAATTAAAAATGAGTTAAATCAATCTAAAGTATATGAGTAAACTGG
TCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCAGTCAGTCATTTGTTCATCC
ACTCCCCGTCGTGAGATAACTACGATACGGGAGGGCTTACCATCTGCCAGTGTGCAATGATACCGC
CACGCTCACCGGCTCCAGATTATCAGCAATAAACAGCCAGCCGAAGGGCGAGCGCAGAAGTGG
TTATCCGCCTCCATCCAGTCTATTAAATTGTTGCCGGGAAGCTAGAGTAAGTAGTGT
CGTCTGCTGTTGGTATGGCTTCAATTAGCTCCGGTCTCCGATCGTGT
GATCAAGGCAGGTTACATGATCCCCATGTTGCAAAAAAGCGGTTAGCT
AGTAAGTTGCCCGCAGTGTATCACTCATGTTATGGCAGCACTG
CATAATTCTCTACTGTATGCG
ATGCTTTCTGTGACTGGTGTAGTACTCAACCAAGTCATTCTGAGA
AAATGTTGATGCGGCCACATAGCAGAACTTAAAGTGCTCAT
CGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTAAAGTGCT
CATATTGAAACGTTCTCGGGG

CGAAAACCTCTAAGGATCTTACCGCTGTTGAGATCCAGTCGATGTAACCCACTCGCACCCAACGTCTTCAGC
ATCTTTACTTCACCAGCGTTCTGGGTGAGCAAAACAGGAAGGCAAATGCCGAAAAAAGGAATAAGGGCGA
CACGGAAATGTTGAATACTCATACTCTCCTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGC
GGATACATATTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTCCCCGAAAAGTGCCACCTGA
C

lentiGuide-Puro

Pink	BsmBI TypeIIs sites for cloning in 20bp sgRNA guide sequence after removing 1.8kb spacer sequence
Green	+85 chRNA sequence for sgRNA
Gray	EF1a promoter sequence
Blue	Puromycin resistance coding sequence

CCCGGGTCAAAGATGGATAAAGTTAACACAGAGAGGAATCTTCAGCTAATGGACCTCTAGGTCTTGAAAGGA
GTGGGAATTGGCTCCGGTCCCCGTCACTGGCAGAGCGCACATGCCACAGTCCCAGAAGTGGGGAGGGGT
CGGCAATTGATCCGGTGCCTAGAGAAGGTGGCGCGGGTAAACTGGAAAGTGTCTGACTGGCTCCGCC
TTCCCGAGGGTGGGGAGAACCGTATATAAGTCAGTAGTCGCGTGAACGTTCTTCGCAACGGGTTGCC
AGAACACAGTAAGTGCCGTGTGGTCCCGCGGGCTGGCTCTTACGGTTATGCCCTTGCCTGCTGAAT
TACTCCACTGGCTGCAGTACGTGATTCTTGATCCCAGCTCGGGTGGAAAGTGGGTGGAGAGTTGAGGCTTG
CGCTTAAGGAGCCCCTCGCCTCGTGTGAGTTGAGGCCCTGGCTGGGCGCTGGGCCCGCGTGCAGATCTGGT
GGCACCTTCGCCCTGCTCGTGTGCTCGATAAGTCAGCCATTAAATTTTGTAGTACCTGCTGCAGCCT
TTTTCTGGCAAGATAGTCTGTAATGCCGGCAAGATCTGCACACTGGTATTCGGTTTGGGCCGCGGGCG
CGACGGGGCCCGTGCCTCCAGCGCACATGGTCGGCGAGGGCCTGCGAGCGCGGCCACCGAGAATGGACGG
GGTAGTCTCAAGCTGGCGGCCTGCTCTGGCCTCGCCGCGTGTATGCCCGCCCTGGCGGAAGG
CTGGCCCGGTGGCACAGTTCGTTGAGCGGAAAGATGGCGCTCCGGCCCTGCTGCAGGGAGCTAAAATGGAG
GACCGCGCGCTCGGGAGAGCGGGGGTGAGTCACCCACACAAAGGAAAAGGGCTTCCGCTCTAGCCGCT
CATGTGACTCACGGAGTACCGGGCGCTCAGGCACCTCGATTAGTTCTGAGCTTTGGAGTACGTGCTTTA
GGTGGGGGGAGGGGTTTATGCGATGGAGTTCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTGGCA
CTTGATGTAATTCTCCTTGAATTGCCCTTTGAGTTGGATCTGGTCAATTCTCAAGCCTCAGACAGTGGTC
AAAGTTTTTCTCCATTTCAGGTGTCGTAACGGCCACCATGACCGAGTACAAGCCCACGGTGCCTGCC
ACCGCGACGACGTCCCCAGGGCGTACGCACCCCTGCCGCCGCTCGCCACTACCCGCCACCGGCCACACGT
CGATCCGGACGCCACATCGAGCGGTACCGAGCTGAAAGAATCTTCCTCACGCGCTGGCTGACATGGCA
AGGTGTGGGTGGACGACGGCGCCGCGTGGCGGTCTGGACCACGCCAGAGCGCTGAAGCGGGGGCGGTGTC
GCCGAGATCGGCCCGCGCATGGCGAGTTGAGCGGGTCCCGCTGGCGCGCAGCACAGATGGAAGGCCCTCTGG
GCCGACCGGCCAAGGAGGCCCGTGGTCCCGCACCGTCGAGTCTGCCCGACACCAGGGCAAGGGCTGG
GCAGCGCCGTCGTGCTCCCGAGTGGAGGGGGCGAGCGCGCCGGGTGCCCGCTTCTGGAGACCTCCGCC
CGAACCTCCCTTACGAGCGCTGGCTTACCGTCACCGCCACGTCGAGGTGCCGAAGGACCGCGCACCTG
GTGCATGACCGCAAGCCGGTGCCTGAACCGTTAACGCTGACAATCACCTGGATTACAAAATTGTAAAGAT
TGACTGGTATTCTTAATATGTTGCTCTTTACGCTATGTTGATACGCTGCTTAATGCTTGTATCATGCTATT
GCTTCCCGTATGGCTTTCATTTCCTCCTGTATAAATCCTGGTCTGTCTTTATGAGGAGTTGGCC
TGTCAAGGCAACGTGGCGTGGTGCACGTGTTGCTGACGCAACCCCCACTGGTGGGATTGCCACACCTGTC
AGCTCCTTCCGGGACTTTCGCTTCCCTCCCTATTGCCACGGGAACCTACGCCCTGCTTGGCTGCT
TGGACAGGGGCTGGCTTGGGACTGACAATTCCGGTGGTGTGGGGAAATCATGTCCTTGGCTGCT
CGCCTGTTGCCACCTGGATTCTGCCGGGACGTCCTCTGCTACGCTCCCTGCCCTCAATCAGCGGACCTC
CTTCCCAGGCCCTGCTGCCGGCTCTGCCGCTTCCCGCTTCCGCTCAGACGAGTCGGATCTCCCT
TGGGCCGCTCCCGCGTCACTTAAGCCAATGACTTACAAGGAGCTGTAGATCTAGCCACTTTAAAAGAA
AAGGGGGGACTGGAAGGGCTAATTCACTCCAACGAAGACAAGATCTGTTTGTACTGGGTCTCTGGTT
AGACCAAGATCTGAGCCTGGAGCTCTGGTAACTAGGAAACCACTGCTTAAGCCTCAATAAGCTTGCCTTGAG
TGCTTAAGTAGTGTGTCGGCTCTGGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCCTTGTAGTGTGG
AAAATCTCTAGCACTACGTTAGTGTGTTTATTCAGTATTATAACTTGCAAAAGAAATGAATATC
AGAGAGTGGAGAGGAACCTGGTTATTGAGCTTAAAGGTTACAAATAAGCAATAGCATCACAAATTCAAAATA
AAGCATTTCCTACTGCAATTCTAGTTGTTGTCACACTGGTAACTAGGAAACCACTGCTTAAGCCTCAATAAGCTTGCCTTGAG
TCCCGCCCCCTAACTCCGCCATCCGCCCTAACTCCGCCAGTCCGCCATTCTCCGCCCTGGCTGACTAATT
TTTTTATTATGCAAGAGGCCGAGGCCGCTCGGCCCTGAGCTATTCCAGAAGTAGTGTAGGAGGTTGGAGG
CCTAGGGACGTACCCATTGCCCTATAGTGAGTCGTTACGCGCTCACTGGCGTGTGTTAACAGTCGTGA
CTGGAAAACCCCTGGCGTTACCAACTTAATGCCCTGAGCACATCCCCCTTCCGCCAGCTGGCGTAATAGCGAAG
AGGCCCGCACCGATGCCCTCCAAACAGTTGCGCAGGCTGAATGGCGAATGGACGCCCTGTAGCGGCCATTA
AGCGCGCGGGGTGGTTACGCGCAGCGTACACTGCCAGGCCCTAGGCCCGCTCCTTCGCTT
CTTCCCTTCTGCCACGTTGCCGGCTTCCCGTCAAGCTAAATGGGGCTCCCTTGGGTTCCGAT
TTAGTGCTTACGGCACCTCGACCCCCAAAAACTGATTAGGGTGTGGGTTACGTAGTGGGCCATGCCCTGATAG
ACGGTTTTGCCCTTGACGTTGGAGTCCACGTTAAATAGTGGACTCTTGTCCAAACTGGAACACACTCAA
CCCTATCTGGTCTATTCTTTGATTATAAGGGATTGCGATTGCCCTATTGGTAAAAATGAGCTGATT

AACAAAATTAACCGAATTAAACAAATATTACCGCTACAATTAGGTGGCACTTTGGGAAATGTGCGCG
GAACCCCTATTGTTATTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCTGATAATGCTT
CAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTCCGTCGCCCTATTCCCTTTGCAGGCTTTG
CCTCCTGTTTGCTACCCAGAAACGCTGGTAAAGTAAAGATGCTGAAGATCAGTGGGTGACGAGTGGTT
ACATCGAACTGGATCTAACAGCGGTAAAGATCCTGAGAGTTTCGCCCGAAGAACGTTTCAATGATGAGCACT
TTAAAGTTCTGATGTGGCGGTATTATCCGTATTGACGCCGGCAAGAGCAACTCGGTGCCGCATACACTA
TTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTACGGATGGCATGACAGTAAGAGAATTAT
GCAGTGCCTGCCATAACCATGAGTATAACACTCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTA
ACCGCTTTTGACACACATGGGGATCATGTAACCGCCTGATCGTTGGAACCGGAGCTGAATGAAGCCATACC
AACAGACGAGCGTACACACAGATGCCGTAGCAATGCCAACACAGTTGCCAAACTATTAACTGGCAACTACTTA
CTCTAGCTTCCCAGCAACAATTAAAGACTGGATGGAGGCGATAAAAGTTGAGGACCAACTTCTGCCCTGCC
CCGGCTGGCTGGTTATTGCTGATAAAATCTGGAGCGGTAGCGTGGGTCTCGCGTATCATTGAGCAGTGGGCC
AGATGTAAGCCCTCCCGTACCGTAGTTACGACAGGGGAGTCAGGCAACTATGATGAACGAAATAGACAGA
TCGCTGAGATAGGTGCCTACTGATTAAGCATTGGTAAGTGCAGACCAAGTTACTCATATAACTTAGATTGAT
TTAAACCTTCATTTAAATTAAAAGGATCTAGGTGAAGATCCTTTGATAATCTCATGACCAAAATCCCTAACG
TGAGTTTCTTCCACTGAGCGTCAGACCCGTAGAAAGATCAAAGGATCTTCTGAGATCCTTTCTGCC
TAATCTGCTGTTGAAACAAAAACCGCTACCGCGTGGTTGCTGGATCAAGAGCTACCAACTT
TTCCGAAGTAACGGCTTCAGCAGAGCGCAGATACCAAAACTGTTCTCTAGTGTAGCGTAGTTAGGCCACCA
CTTCAAGAACTCTGTAGCACCGCTACATACCTCGCTGCTAACCTCTGTTACAGTGGCTGCTGCCAGTGGCATA
AGTCGTGTCTTACCGGGTTGACTCAAGACGATAGTTACCGATAAGGCGCAGCGTGGCTGACGGGGTTCG
TGCACACAGCCCAGCTGGAGCGAACGACCTACCGCAACTGAGACACCTACAGCGTGAGCTATGAGAAAGGCCAC
GCTTCCCAGGGAGAAAAGCGGACAGGTATCCGTAAGCGCAGGGTGGAAACAGGAGAGCGCAGGAGGCTTC
CAGGGGGAAACGCCTGGTATCTTATAGTCCTGCGGTTGCCCCACTCTGACTTGAGCGTCGATTTGTGATGC
TCGTCAAGGGGGCGGAGCCTATGAAAAACGCCAGCAACGCCGCTTTTACGGTTCTGGCCTTTGCTGCC
TGCTCACATGTTCTTCTGCTTATCCCTGATTCTGTTACCGTATTACCGCTTGAGTGTGAGCTGATACCG
CTCGCCCGAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCAATACGAAACCGCT
CTCCCCCGCGTGGCGATTCTAACATGAGCTGGCACGACAGGTTCCGACTGGAAAGCGGGCAGTGAGCGCAA
CGCAATTAAATGAGCTGAGCTACCTACAGGACCCAGGTTACACTTATGCTTCCGGCTCGTATGTTGTG
GAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAGCGCAATTAAACCTCAC
TAAAGGGAAACAAAGCTGGAGCTGAAAGCTTAATGAGCTTATGCAAACTCTTGAGTCTGCAACATGGTAACG
ATGAGTTAGCAACATGCCCTACAAGGAGAGAAAAGCACCGTGATGCCATTGGTGGAAAGTAAGGTGGTACGATCG
TGCCTTATTAGGAAGGAAACAGACGGGCTGACATGGATTGGACCAACTGAAATTGCCGATTGAGAGATATTG
TATTTAAGTGCCTAGCTGATACATAACGGGCTCTCTGTTAGACCAGATCTGAGCCTGGAGCTCTGGCTAA
CTAGGGAAACCACTGCTTAAGCCTAACAAAGCTTCTGAGTCTCAAGTGTGAGTCTGAGCTGCTGTTGTGA
CTCTGGTAACTAGAGATCCCTAGACCCCTTGTAGTCAGTGTGGAAAATCTAGCAGTGGGCCAACAGGACTT
GAAAGCGAAAGGGAAACCAAGAGGAGCTCTCGACGCAGGACTCGGCTGTAAGCGCAGCGCAAGAGGCGAGG
GGCGCGACTGGTGAGTACGCCAAATTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGT
ATTAAGCGGGGGAGAATTAGATCGCATGGGAAAAAATTGGTTAACGCCAGGGGGAAAGAAAAATATAAATTAAA
ACATATAGTATGGCAAGCAGGGAGCTAGAACGATTGCAAGTTAACCTGGCTGTTAGAAACATCAGAAGGCTGA
GACAAATACTGGACAGCTACAACCATCCCTCAGACAGGATCAGAACACTAGATCATTATATAACAGTAGCA
ACCCCTATTGTCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTACAGAACAGGAGATGGGACAATTGGAGA
AGTAATTATATAAATAAAGTAGTAAAAATTGAAACCTTACAGGAGTAGCACCCACCAAGGAAAGAGAGTGGT
GCAGAGAGAAAAAGAGCAGTGGGAAATAGGAGCTTGTGCTTGGGTTCTGGGAGCAGCAGGAAGCACTATGGCG
CAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGCTGGTATAGTCAGCAGCAGCAAACTTGCTGAGG
GCTATTGAGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGACATCAAGCAGCTCCAGGCAAGAACCTGGCTGT
GGAAAGATACTAAAGGATCAACAGCTCTGGGATTGGGTTCTGGAAAACCTATTGACCAACTGCTGTG
CTTGGAAATGCTAGTTGAGTAATAATCTGGAACAGATTGGAAATCACAGCACCTGGATGGAGTGGACAGAGAA
ATTAACAATTACACAAGCTTAATACACTCCTAACCTGAAAGAACGCAAGAACAGCAAGAAAAGAATGAAACAAGAATT
ATTGGATTAGATAATGGCAAGTTGTGAAATTGGTTAACATAACAAATTGGCTGTTAGTATAAAATTATTCA
TAATGATAGTAGGAGGCTGGTAGGTTAACGAAATAGTTCTGTAACCTATAGTGAATAGAGTTAGGCAGGGA
TATTCACTTACGTTACAGACCCACCTCCAACCCGAGGGGACCCAGAGAGGGCCTATTCCCATGATTCTTC
ATATTGCTATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAAATTGACTGTAACACAAAGATATTAGTAC
AAAATACGTGACGTAGAAAGTAATAATTCTGGTAGTTGCAACTTAAATTGTTAAATGTTAAATGGACTATCAT
ATGCTTACCGTAACGGAAAGTATTGCAATTCTGGTTATATCTGTTAGGAAAGGACGAAACACGGAGACGG
TTGTAATGAGCACACAAAATACATGCTAAATATTATATTCTATGACCTTATAAAATCAACAAAATCTTCTT
TTAATAACTTAGTATCAATAATTAGAATTGGTTATGTCCTTTGCAAACCTTTAACAAAATGAGCAAATAAA

AAAACGCTAGTTTAGTAACCGCGTTGTTTCTCACCTTAATAATAGCTACTCCACCACTGTTCTAACGGT
CAGCTCCTGCTCAATCATTTTGAGCATCTCAAATGTTCAACTCCACCAAGCTGCTTAACAAAGCATTGTCT
TTAACAACTGACTTCATTAGTTAACATCTCAAATGTTGACCTGACCTGATTTGAAAATCCTGTTGATGTTAACAAA
TTCTAATCCAGCTCAACAGCTATTCACAAGCTTCACTGATTTCTCTTGTAAATAAACAAATTTCATAAATAC
ATTTAACAAACATGTGATCCAGCTGCTTTTACAGCTTCACTGCTTCAAAACTAATTCTAATTTGTCTTT
AATGCACCAATATTAATACCATATCAATTCTGTTGACCATCTTAATTGCTTCAGAAACTTCGAATGCTTTGT
AGCTGTTGTCATGCACCTAGAGGAAAACCTACAACATTGTTATTCTACATTGTCCTTAAATAATTCTTAC
AATAGCTTGTCAATATGAATTAAACACAAACTGTTGCAAATCAAATTCAATTGCTTCACTCACATAATTGTTAATT
TCAGCTTCTGAGCATCTGTTAATAATGTTGATCTATATATTGTTAGTTCTTCTATATATT
ATTTTAATTCTTAATAATTGCTACTTTAACAGATTCAACACCTATAAA
ATAAAATTCTTAGTTAGGTTCAAGTCCACTGGGCGAACAGCAAATCATGACTTATCTCTAAATAAAATTCTAGTA
AGCTTGTCTGGCATATTACATCCATCGATGTTGACTTCAACATTAAACATTAAAGTCCAGCAATTGAGTT
AAGGGTGTGCTCTCATGATTCTATTAAATAGGTTCAATTAAATTCTTCTTCTGTTAAATTCAAGTTAA
AGTGAAAGTGTAAATATGCACCCATTCTAAATAATCTTAAATAGTCTACTAATGTTTATTGTTTATTTGTTTAT
AAAATCAAGCAGCCTCTGCTATTAAATATAGAAGCTTGTATTCCATCTTATCTAGCTGAGTCATCAATTACATAT
CCATAACTTCTTCATAAGCAAAAACAAATTAAATCGTTATCTTCTTCTAGCAATTCTCTACCCATTCTT
AAATCCAGTTAAAGTTTACAATATTAACCATATTTCATGAGCGATTCTATCACCCAAACTACTGTTACAA
AACTTGAATATAGAGCGGATTGGAAATGCTATTAAAGCTTTAGATTGATAATTTCATCAATTAAATT
GGTCTGTTGATTCCATCTAAATCTTACAAAATGACCATCATGTTTATTGCCATTCAAATCTGTCAGCATCTGG
GTCATTCTAAATATAATCTGCATCATGTTAATACCATTAAAGCGGTATTCTCATGCAGGATCAAATTCTG
GATTGGATTACAACATTAAATGTTCATCTTCAAATGCATGCTCTCAACCTCAAACGTTATATCCTGAT
TCACGTAATATTGTTGGGTAAATTAGTTCTGTTCCATTAACTGCGCTAAAATAATTAAATCTTCTAGC
TTCTGCTCTTTGTCAGTCTCTGTTAGAGCTAGAAATAGCAAGTAAATAAGGCTAGCCGTTATCAACTT
GAAAAAGTGGCACCGAGTCGGTGCTTTTAAGCTTGGCGTAACTAGATCTGAGACAAATGGCAGTATTCTCAC
AATTAAAGAAAAGGGGGATTGGGGGTACAGTGCGAGGGAAAGAATAGTAGACATAATAGCAACAGACATACA
AACTAAAGAATTACAAAACAAATTACAAAATTCAAATTTGGGTTATTACAGGGACAGCAGAGATCCACTT
GGCGCCGGCTCGAGGGGG

References

1. Shalem, O. *et al.* Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* **343**, 84–87 (2014).
2. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**, 1105–1111 (2009).
3. Trapnell, C. *et al.* Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* **7**, 562–578 (2012).
4. Merkin, J., Russell, C., Chen, P. & Burge, C. B. Evolutionary dynamics of gene and isoform regulation in Mammalian tissues. *Science* **338**, 1593–1599 (2012).
5. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25 (2009).
6. Hsu, P. D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol* **31**, 827–832 (2013).
7. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res* **42**, D68–73 (2014).
8. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal* **17**, 10–12 (2011).